Novel compound SK-1009 suppresses interleukin-6 expression through modulation of activation of nuclear factor-kappaB pathway

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 12, 2012, Pages 2186-2191

  Shimura, Misato ^a,b   Yamamoto, Masafumi ^a   Fujii, Gen ^a   Takahashi, Mami ^a   Komiya, Masami ^a   Noma, Nobuharu ^a,b   Tanuma, Sei Ichi ^b   Yanaka, Akinori ^b,c   Mutoh, Michihiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Colon; Interleukin 6; Nuclear factor kappab; SK 1009

Indexed keywords

ANTINEOPLASTIC AGENT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; SK 1009; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; ISOINDOLES; MACROPHAGES; NF-KAPPA B; OXAZOLES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84871545679     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00575     Document Type: Article

References (27)

1. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med., 14, 222-231 (2008).
2. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev., 13, 357-368 (2002).
3. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J. Gastroenterol., 47, 97-106 (2012).
4. Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J. Clin. Lab. Anal., 24, 256-261 (2010).
5. Fuksiewicz M, Kowalska M, Kotowicz B, Rubach M, Chechlinska M, Pienkowski T, Kaminska J. Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer. Clin. Chem. Lab. Med., 48, 1481-1486 (2010).
6. Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami HO, Glimelius B, Molin D, Hamilton-Dutoit S, Melbye M, Hjalgrim H. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin. Cancer Res., 14, 6974-6978 (2008).
7. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin. Colorectal Cancer, 7, 331-337 (2008).
8. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol., 26, 4820-4827 (2008).
9. Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 294, R393-R401 (2008).
10. Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, Wakabayashi K. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev. Res. (Phila.), 4, 445-453 (2011).
11. Barton BE. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin. Ther. Targets, 9, 737-752 (2005).
12. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res. Ther., 8 (Suppl. 2), S5 (2006).
13. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med., 177, 1779-1784 (1993).
14. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappaB/ Rel in induction of nitric oxide synthase. J. Biol. Chem., 269, 4705-4708 (1994).
15. Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJ. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J. Biol. Chem., 272, 1226-1230 (1997).
16. Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K. Involvement of a NF-kappaB-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol. Cell. Biol., 10, 561-568 (1990).
17. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappaB transcription factor. Mol. Cell. Biol., 10, 2327-2334 (1990).
18. Zhang YH, Lin JX, Vilcek J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappaB-like sequence. Mol. Cell. Biol., 10, 3818-3823 (1990).
19. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, Akira S. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. U.S.A., 90, 10193-10197 (1993).
20. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 336, 1066-1071 (1997).
21. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol., 10, 405-455 (1994).
22. Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of I kappaB-alpha is necessary for activation of transcription factor NF-kappaB. Nature, 365, 182-185 (1993).
23. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science, 267, 1485-1488 (1995).
24. Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS, Keefer LK. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science, 254, 1001-1003 (1991).
25. Liu RH, Jacob JR, Hotchkiss JH, Cote PJ, Gerin JL, Tennant BC. Woodchuck hepatitis virus surface antigen induces nitric oxide synthesis in hepatocytes: possible role in hepatocarcinogenesis. Carcinogenesis, 15, 2875-2877 (1994).
26. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res., 305, 253-264 (1994).
27. Haswell-Elkins MR, Satarug S, Tsuda M, Mairiang E, Esumi H, Sithithaworn P, Mairiang P, Saitoh M, Yongvanit P, Elkins DB. Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. Mutat. Res., 305, 241-252 (1994).